StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) company profile

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.04+0.06 (+0.55%)

Close on Nov 17, 2026Market cap $5.40BP/E –Yield –

About Gossamer Bio

Pharmaceutical Preparations, SIC 2834

Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic treatments for pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company's primary investigational product candidate is seralutinib, an inhaled kinase inhibitor targeting PDGFR, CSF1R, and c-KIT pathways designed to address the underlying cellular overgrowth in lung blood vessels. Additionally, the company holds an option agreement to develop RT234, an investigational inhaled dry-powder formulation intended for on-demand symptom management. Its target population comprises patients suffering from progressive pulmonary vascular and fibrotic lung diseases.

The company operates globally through clinical research and development partnerships, including a collaboration agreement with Chiesi to co-develop seralutinib. Under this arrangement, the company leads global development and United States commercialization for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, while Chiesi maintains commercialization rights in other international territories. The provided text does not state the company's headquarters location.

Summary of the business section of Gossamer Bio's latest annual report, written by StockData.

Company profile

Company

Legal name
Gossamer Bio, Inc.
Headquarters
San Diego, CA
Address
3115 Merryfield Row, Suite 120 92121
Phone
(858) 684-1300
Employees
161, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
GOSS
Exchange
Nasdaq
IPO date
Feb 8, 2019
Shares outstanding
489M, Aug 8, 2026
Public float
$270.80M, Jun 28, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-80 reverse, Sep 11, 2026
SEC CIK
1728117
CUSIP
38341P201
ISIN
US38341P2011
FIGI
BBG00MVWLLM2
Share class FIGI
BBG00MVWLMC1
LEI
549300ZOC0N2W6PSFR58
EIN
47-5461709

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Faheem HasnainPresident & CEO, Director6,245,866
Caryn PetersonChief Development Officer259,333
Waage ChristianEVP, Tech Ops and Admin882,175
Bryan GiraudoCOO/CFO869,747
Robert Paul Smith JRChief Commercial Officer285,898
Richard ArandaChief Medical Officer465,645
Russell J. CoxDirector7,200
John D. QuiselDirector–
Gregory Austin CiongoliDirector–
Skye DrynanDirector–
Sandra MilliganDirector90,050
Steven D. NathanDirector–
Thomas O. DanielDirector38,095

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.30M$9.20M$1.22M$143–
FY2024$2.01M$1.86M$1.12M$42–
FY2023$2.10M$1.59M$1.31M$42–
FY2022$7.26M-$1.91M$2.88M$22–
FY2021$4.75M$6.34M$2.24M$117–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 8, 2019
Offer price
$16.00
Securities offered
17,250,000
Gross proceeds
$276.00M
Exchange
Nasdaq
First trading day
Feb 8, 2019
First-day close
$17.94+12.1%
Lock-up ends (est.)
Aug 7, 2019

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 10, 2026, we had 161 full-time employees and 1 part-time employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?